3 recruiting. 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Recruiting 3 |
Follow Malignant Solid Tumors: new trials by email Literature Review of Malignant Solid Tumors trials Research Report on Malignant Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CAIX-targeted PET/CT in Solid Tumors 68Ga-CAIX - Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma | Not applicable | Recruiting | Zhongnan Hospital | 100 | 2026-09-21 | 2026-10-13 |
| The Effect of Serum Ferritin in irAE PD-1 and PD-L1 inhibitor, Targeted drugs, chemotherapy drugs - Immune-related Adverse Event, Malignant Solid Tumors | Not applicable | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 1500 | 2024-07-04 | 2024-11-25 |
| Characterization of Hyperpolarized Pyruvate MRI Reproducibility Hyperpolarized Pyruvate - Malignant Solid Tumors | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 109 | 2015-04-01 | 2026-07-21 |
Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Lung Neoplasms (1)
Adenocarcinoma (1) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Kidney Neoplasms (1) · Lung Diseases (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1)
Antineoplastic Agents (1) · Immune Checkpoint Inhibitors (1)
Memorial Sloan Kettering Cancer Center (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Zhongnan Hospital (1)
China (2) · United States (1)
Kayvan Keshari, PhD (1) · Xiubao Ren, M.D, Ph.D (1) · Yong He, MD, PhD (1)